Bahareh Abbaspanah, Samira Reyhani and Seyed Hadi Mousavi* Pages 454 - 464 ( 11 )
Mesenchymal Stem Cells (MSCs) enable a novel approach to stem cell therapy. Bone Marrow (BM) was the first source used in MSCs therapy. However, BM has a number of key limitations as a source of MSCs, such as the existence of only a small number of MSCs in the tissue; the painful, ethically problematic, and invasive nature of the associated collection process; and a decrease in MSC specifications as the age of donors increases. As a result, there has been increasing scholarly attention towards identifying alternative sources for MSCs. In specific, Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) have been identified as a valuable source from which MSC may be obtained with potentially fewer ethical issues. MSCs can regulate the immune response, promote tissue repair, increase regeneration, and improve anticancer effects. Thus, they are significant allogenic and autologous representatives for curing malignant and non-malignant disorders. In this review, therefore, the prospective applications for curing autoimmune disorders will be considered.
Umbilical cord, mesenchymal stem cells, autoimmune disease, stem cell therapies, bone marrow, non-malignant disorders.
Royan Stem Cell Technology Company, Cord blood bank, Tehran, Department of Laboratory Sciences, School of Allied Medical sciences, Tehran University of Medical sciences, Tehran, Department of Hematology, School of Allied Medical Sciences, Tehran University of Medical sciences, Tehran